Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Cortisol Testing to Diagnose Adrenal Insufficiency Following Adrenalectomy for Mild Autonomous Cortisol Secretion
Hamidi, Oksana , Salama, Bahaa , Findling, James W. , Zhang, Catherine D , Dream, Sophie , Balderrama-Brondani, Vania , Dackiw, Alan P.B., Mirfakhraee, Sasan , Mehta, Ankeeta , McKenzie, Travis J. , Foster, Trenton R. , Findling, James W , Balderrama-Brondani, Vania , Mirfakhraee, Sasan , Foster, Trenton, Bancos, Irina , Hamidi, Oksana , Wang, Tracy S. , Carroll, Ty B , Sada, Alaa , Dogra, Prerna , Oltmann, Sarah Catherine , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 12, 2025 | Volume: 111 | Issue: 3 | Pages: 665-678

10.1210/clinem/dgaf515 | PMID 40966719 Get It

Abstract Context Patients with mild autonomous cortisol secretion (MACS) can develop adrenal insufficiency after unilateral adrenalectomy. Objective This work aimed to determine the prevalence, duration, and predictors of adrenal insufficiency, and compare postoperative basal cortisol and cosyntropin stimulation test (CST). Methods In this multicenter retrospective study of patients with MACS, adrenal insufficiency was diagnosed when postoperative basal cortisol was less than 10 µg/dL and/or CST < 18 µg/dL. The results were concordant when both tests met cutoffs. Biochemical (BSS) and clinical severity scores (CSS) were calculated. Results Among 281 patients with MACS (80% women), postoperative adrenal insufficiency was diagnosed in 153 (54.5%) patients. Adrenal insufficiency inversely correlated with age (odds ratio [OR] 0.67 per 10 years; 95% CI, 0.53-0.84). Low basal cortisol and CST were associated with younger age (OR 0.64 per 10 years for both) and higher BSS (OR 1.17 and 1.22, respectively). Basal cortisol and CST were discordant in 22% of patients, and the discordance rate was more common in patients with bilateral nodules (32% vs 19%; P < .001). The median time to adrenal insufficiency recovery was 3.9 months (IQR, 3-5.9 months), with longer duration associated with higher BSS and CSS: 3 months for mild, 4 to 5 months for moderate, and 12 to 14 months for severe BSS and CSS. Conclusion Approximately half of patients with MACS developed postoperative adrenal insufficiency, with 50% recovering by 3.9 months after surgery. BSS correlated with basal cortisol, CST, and duration of adrenal insufficiency. As discordant results were noted in 22%, performing both basal cortisol and CST postoperatively should be considered.
Cerebral haemodynamic responses to inspiratory muscle work
Ramsook, Andrew H. , Pruter, Wyatt W. , Webb, Kevin L. , Ataie, Amin , Webb, Kevin L , Joyner, Michael J , Ramsook, Andrew H , Hughes, Morgan A , Ataie, Ali, Wiggins, Chad C. , Dillon, Gabrielle A. , Baker, Sarah E. , Joyner, Michael J.

Mayo Clinic

Experimental Physiology | September 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1113/ep092840 | PMID 40936248 Get It

AbstractFatiguing inspiratory work has been shown to evoke a sympathetically mediated reflex that has systemic cardiovascular consequences, including increases in heart rate and blood pressure and a decrease in resting limb vascular conductance. Moreover, the response to this reflex appears to be attenuated in females compared with males. It remains to be seen whether this respiratory muscle metaboreflex also exerts an effect on cerebral blood flow. Cerebral blood flow is tightly regulated to maintain homeostasis and critical function. Therefore, it stands to reason that cerebrovascular haemodynamics would not be compromised through this respiratory muscle metaboreflex. We hypothesized that fatiguing inspiratory work would reduce resting limb conductance, but cerebral blood flow would be minimally impaired. Females (34 ± 10 years old, n = 12) and males (31 ± 8 years old, n = 12) performed a 5 min, high‐intensity bout of inspiratory pressure threshold loading (IPTL) designed to evoke the respiratory muscle metaboreflex. In response to IPTL, mean arterial pressure increased in both males and females (p < 0.001), and limb vascular conductance decreased to a greater degree in males than in females (p = 0.005). The cerebrovascular conductance index was higher in females (p = 0.007) but not affected by IPTL (p = 0.417). Our findings suggest that cerebral blood flow is spared from the redistribution of blood flow in response to fatiguing inspiratory work and that this protection is true in both males and females.
Sulcal morphology in former American football players
Jung, Leonard , Mirmajlesi, Anya S, Stearns, J. W. , Breedlove, Katherine M. , John, Omar , Kim, Nicholas , Wickham, Alana, Protas, Hillary , Baucom, Zachary, Tuz‐Zahra, Fatima , Wiegand, Tim L. T. , Billah, Tashrif , Pasternak, Ofer, Im, Brian , Datta, Shae , Bernick, Charles , Balcer, Laura J. , Alosco, Michael L. , Lin, Alexander , Cummings, Jeffrey L., Reiman, Eric M. , Arciniega, Hector , Boker, Connie, Kowall, Neil W. , Otis, James , Weller, Jason , Simkin, Irene, Andino, Alondra, Diamond, Courtney , Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Rice, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Pasternak, Ofer , Arcinieago, Hector, Coello, Eduardo , Coleman, Michael J. , Jung, Leonhard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Marmar, Charles R. , Hasanaj, Lisena, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard M., Johnson, Keith A. , Jung, Leonard B , Stearns, Jared , Breedlove, Katherine , Tripodis, Yorghos , Adler, C H , Alosco, Michael L , Koerte, Inga K , Arciniega, Hector , Su, Yi , Tripodis, Yorghos , Daneshvar, Daniel H. , Heller, Carina , Coleman, Michael , Adler, Charles H. , Stern, Robert A. , Shenton, Martha E. , Bouix, Sylvain , Chen, Kewei , Au, Rhoda , Cantu, Robert C. , Farrer, Lindsay A. , Helm, Robert H. , Katz, Douglas I. , Mez, Jesse , Mercier, Gustavo , Conneely, Shannon E. , Diamond, Courtney, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Miller, Jason Rafe , Sabbagh, Marwan Noel , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Bellgowan, Patrick S.F. , Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Kirov, Ivan I. , Lui, Yvonne W. , George, Allan, Riley, Edward P. , Cummings, Jeffrey L.

Mayo Clinic

Brain Communications | September 9, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcaf345 | PMID 41048544 Get It

Abstract Repetitive head impacts are associated with structural brain changes and an increased risk for chronic traumatic encephalopathy, a progressive neurodegenerative disease that can only be diagnosed after death. Chronic traumatic encephalopathy is defined by the abnormal accumulation of phosphorylated tau protein, particularly at the depths of the superior frontal sulci, suggesting that sulcal morphology may serve as a relevant structural biomarker. Contact sport athletes, such as former football players, are at elevated risk due to their prolonged exposure to repetitive head impacts. Cortical atrophy linked to underlying tau accumulation may result in shallower and wider sulci, potentially making sulcal morphology an imaging marker for identifying individuals at risk for this disease. This study investigated sulcal morphological differences in former football players and examined associations with age, football-related exposure, clinical diagnosis of traumatic encephalopathy syndrome, levels of certainty for chronic traumatic encephalopathy pathology, neuropsychological performance, and positron emission tomography imaging using flortaucipir. We analysed structural magnetic resonance imaging data from 169 male former football players (mean age 57.2 (8.2) years, range 45–74) and 54 age-matched, unexposed asymptomatic male controls (mean age 59.4 (8.5) years, range 45–74). Sulcal depth and width were quantified using the CalcSulc, focusing on two regions in each hemisphere commonly affected by chronic traumatic encephalopathy pathology: the superior frontal and occipitotemporal sulci. Generalized least squares models were used to assess group differences and interactions with age and football exposure variables, including age of first exposure, total years played, and cumulative head impact exposure. An analysis of covariance evaluated relationships between sulcal morphology, clinical measures, and flortaucipir uptake, adjusting for age, race, body mass index, education, imaging site, apolipoprotein E4 status, and total intracranial volume. Former football players demonstrated significantly shallower sulcal depth in the left superior frontal sulcus compared to unexposed controls. Earlier age of first exposure and longer football careers were associated with greater widening of the left occipitotemporal sulcus. Higher cumulative head impact exposure was linked to reduced sulcal depth in the left superior frontal region. However, sulcal morphology was not associated with clinical diagnosis, levels of certainty, neuropsychological test performance, or flortaucipir imaging. These findings suggest that sulcal morphology may reflect cumulative exposure to repetitive head impacts, particularly in brain regions vulnerable to chronic traumatic encephalopathy pathology. Future ante- and post-mortem validation studies are needed to determine whether sulcal morphology can serve as a reliable in vivo biomarker of risk.
Influence of Surgical Technique and Surgical Skill on Outcomes of Cleft Palate Repair
Kirschner, Richard E. , Temkit, M’hamed , Baylis, Adriane L. , Hardin-Jones, Mary , Pollard, Sarah Hatch , Chapman, Kathy , Gosain, Arun K. , Sitzman, Thomas J. , Chee-Williams, Jessica L. , Chapman, Kathy L.

Mayo Clinic

Plastic & Reconstructive Surgery | September 8, 2025 | Volume: 157 | Issue: 4 | Pages: 551e-562e

10.1097/prs.0000000000012422 | PMID 40920490 Get It

Background: There remains significant uncertainty about the fistula rate following palate repair with the Furlow double opposing Z-plasty (Furlow DOZ) technique compared with a straight-line/mucosal incision with intravelar veloplasty (IVVP) technique. Moreover, the relative impact of technique and surgical skill on fistula incidence remains unclear. Methods: A prospective, observational study of cleft palate repair was conducted. Enrollment occurred at 18 U.S.-based cleft centers, including 64 cleft surgeons. The primary outcome was postoperative fistula. Results: Overall, 1219 participants underwent cleft palate repair, 1178 of whom presented for follow-up. Of these, 581 (49.3%) underwent palate repair with the Furlow DOZ technique, 483 (41.0%) with the straight-line/IVVP technique, and 114 (9.7%) with an alternative technique. The overall fistula incidence was 5.3% (62 of 1162 analyzed for fistula occurrence). The fistula incidence was significantly lower in the Furlow DOZ group (2.4% [14 of 564]) than in the straight-line/IVVP group (7.8% [37 of 427]), with a propensity score–weighted risk difference of 5.7% (95% CI, 1.6% to 9.9%; P = 0.007). The fistula incidence varied substantially among surgeons: the top quartile’s fistula rate was 0% (0 fistulas among 417 repairs), whereas the bottom quartile’s fistula rate was 18.9% (31 fistulas among 164 repairs). Conclusions: Fistula incidence following cleft palate repair was significantly lower when using the Furlow DOZ technique, compared with the straight-line/IVVP technique. The effect of surgical technique was smaller, however, than the variation observed between the top and bottom quartiles of surgeons. These findings suggest that changing surgical technique may lead to small changes in fistula incidence, but greater opportunities exist to improve outcomes by improving surgical skill.
Radiotherapy for Growing Vestibular Schwannomas
Sethi, Mantegh , Gowrishankar, Shravan , Mannion, Richard , Guilfoyle, Mathew R., Buttimore, Juliette , Gamazo, Nicola, Duke, Simon, Jena, Raj, Burton, Katherine , Fornezza, Umberto, Perini, Zeno, Mari, Cristina , Gazzola, Luca, Schouten, Sammy M , Kunst, Henricus P. M. , Bassi, Rohan, MacKeith, Samuel , Whitfield, Gillian , McBain, Catherine , Hotchkies, A , Lloyd, Simon , Obholzer, Rupert , Cheang, Ya Fang Amanda, Thomas, Nick, Barazi, Sinan, Maratos, Eleni, Hassan, Sheila, Tancu, Cornel, Kitchen, Neil , Marinelli, John P. , Carlson, Matthew L., Link, Michael J. , Tysome, James Russell , Donnelly, Neil P. , Axon, Patrick , Bance, Manohar , Jena, Raj, Burton, Katherine, Jefferies, Sarah , Mari, Cristina, Gazzola, Luca , Compter, Inge , Eekers, Daniëlle B. P. , Jeyaretna, Deva Sanjeeva , Colaco, Rovel J. , Shapey, Jonathan , Carlson, Matthew L. , Borsetto, Daniele

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | September 4, 2025 | Volume: 151 | Issue: 10 | Pages: 931

10.1001/jamaoto.2025.1953 | PMID 40906473 Get It

Importance In the literature, there is a lack of data reporting tumor control rates after radiotherapy in actively growing vestibular schwannomas (VS). Data for this rarely studied population are needed. Objective To estimate tumor control rates in radiologically growing VS treated with first-line radiotherapy. Design, Setting, and Participants This international, multicenter cohort study used prospectively collected data from patients with growing unilateral VS treated first-line with radiotherapy between January 2000 and December 2023 from 8 tertiary referral skull base units. The data were analyzed in June 2025. Exposures Radiotherapy as an initial treatment for VS. Main Outcomes and Measures The primary outcome was treatment failure, ie VS growth postradiotherapy, which was predefined as an increase in maximum intracranial tumor diameter (ICTD) of 3 mm or greater within the first 2 years after radiotherapy or 2 mm or greater thereafter. Secondary outcomes were treatment failure based on different definitions of VS growth: (1) an increase in ICTD of 2 mm or greater, (2) an increase in ICTD of 3 mm or greater, and (3) conversion to surgery. Results A total of 1883 patients (975 female individuals [51.8%]; median age at diagnosis, 63 years [IQR, 53-71 years]) were included in the study. Using the primary definition of treatment failure (an increase in ICTD of ≥3 mm within the first 2 years postradiotherapy or ≥2 mm thereafter), the Kaplan-Meier estimate yielded a 10-year tumor control rate of 76.1% (95% CI, 72.7%-79.2%). For secondary outcome definitions, 10-year tumor control rates were 60.1% (95% CI, 57.5%-64.3%) for an ICTD increase of 2 mm or greater, 78.3% (95% CI, 75.0%-81.2%) for an increase of 3 mm or greater, and 92.6% (95% CI, 90.4%-94.3%) for conversion to surgery. Neither pretreatment tumor size nor tumor location (intracanalicular vs extracanalicular) were significantly associated with treatment failure. Conclusions and Relevance The results of this cohort study provide tumor control outcomes for radiologically growing VS treated with radiotherapy using several clinically relevant definitions of growth. By focusing exclusively on this rarely isolated subgroup, the findings offer targeted data to potentially inform treatment expectations and future research.
Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients
Oh, Ju‐Hee , Reed, Sarah K, Riviere-Cazaux, Cécile , Mladek, Ann C. , Caron, Alissa, Mohammad, Afroz S., Hu, Leland , Kizilbash, Sani H. , Geyer, Susan, Elmquist, William F. , Sarkaria, Jann N. , Dixon, Jesse G. , Kaufmann, Timothy J , Kizilbash, Sani, Giannini, Caterina , Galanis, Evanthia , Sarkaria, Jann N , Kizilbash, Sani H , Mladek, Ann C , Reed, Sarah K, Kim, Minjee , Illamola, Sílvia M. , Zhang, Wenjuan , Vaubel, Rachael A. , Regan, Michael S. , Birnbaum, Angela K. , Zhang, Wenqiu , Kaufmann, Timothy J. , Daniel, J. , Agar, Nathalie Y.R. , Giannini, Caterina , Parney, Ian F. , Galanis, Evanthia , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | September 3, 2025 | Volume: 28 | Issue: 1 | Pages: 130-142

10.1093/neuonc/noaf204 | PMID 40916832 Get It

Abstract Background Disruption of the blood–brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs. Methods Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning. Cefazolin and levetiracetam were administered prior to skin incision, and serial plasma and image-registered tumor samples were collected during the operation. Drug levels were measured by LC-MS/MS, tissue drug levels were corrected for residual blood, and tumor-to-plasma concentration ratios were calculated. Intraoperative microdialysis was performed in a subset of patients to measure the same two drugs. Results Tumor (n = 125) and plasma (n = 261) samples were available for analysis from 42 operative cases. Across all samples, the tumor-to-plasma ratio was significantly lower for cefazolin (marginal mean [MM]: 0.15, 95% CI: 0.11–0.19) as compared to levetiracetam (MM: 0.70, 95% CI: 0.64–0.75; P &lt; .001). When compared between contrast-enhancing and non-enhancing regions, tumor-to-plasma ratios for cefazolin varied by 4.4-fold (0.27, 95% CI: 0.20–0.35 vs. 0.06, 95% CI: 0.04–0.08, respectively; P &lt; .001), and varied for levetiracetam by 1.4-fold (0.88, 95% CI: 0.78–0.97 vs. 0.61, 95% CI: 0.55–0.66, respectively; P &lt; .001). These results were confirmed with the intra-operative microdialysis and a population pharmacokinetic analysis. Conclusions This study demonstrates significant inter- and intra-tumoral heterogeneity in drug delivery for both levetiracetam and cefazolin within high-grade brain tumors that is not necessarily predicted by clinical MR imaging and may reflect tumor-induced changes in both perfusion and BBB integrity.
The role of α 2 -adrenergic mechanisms in sympathetic baroreflex control of human blood pressure
Spafford, Julia, Limberg, Jacqueline K. , Wiggins, Chad C. , Iannarelli, Nathaniel , Senefeld, Jonathon W. , Nicholson, Wayne T. , Shoemaker, J. Kevin , Spafford, Julia E , Harvey, Ronée E , Wiggins, Chad C , Iannarelli, Nathaniel J , Senefeld, Jonathon W , Curry, Timothy B. , Joyner, Michael J , Shoemaker, J Kevin , Baker, Sarah E , Klassen, Stephen A , Harvey, Ronée E. , Joyner, Michael J. , Baker, Sarah E. , Klassen, Stephen A.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | September 3, 2025 | Volume: 329 | Issue: 5 | Pages: H1229-H1243

10.1152/ajpheart.00403.2025 | PMID 40897446 Get It

Intravenous dexmedetomidine infusion (selective α 2 -adrenergic receptor agonist) 1) reduced the firing probability and strength of baroreflex control over medium-sized sympathetic action potentials in muscle sympathetic nerve activity (MSNA) and 2) attenuated the transduction of MSNA bursts to changes in blood pressure (BP) by reducing the magnitude of BP responses and increasing the time to peak BP. These data suggest that neural and vascular α 2 -adrenergic mechanisms contribute to sympathetic baroreflex regulation of human BP.
A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis
Striebich, Christopher C. , Feser, Marie L. , O’Dell, James R., James, Judith A. , Sparks, Jeffrey A. , Davis, John M. , Graf, Jonathan , McMahon, Maureen , Solow, E. Blair , Forbess, Lindsy, Tiliakos, Athan, Schiopu, Elena , Horowitz, Diane , Strickland, C. , Arriens, Cristina , Grossman, Jennifer M. , Frazer‐Abel, Ashley , Fleischer, Chelsie , Greenleaf, Melissa E., York, Kate, Walker, Sarah , Keyes‐Elstein, Lynette, Byron, M., Goldmuntz, Ellen, Holers, V. Michael , Deane, Kevin D , James, Judith A , Sparks, Jeffrey A , Davis, John M , McMahon, Maureen , Kay, Jonathan , Fedler, Janel , Holers, V Michael , Tiliakos, Athan, Danila, Maria I. , Guthridge, Joel M. , Demoruelle, Mary Kristen , Bemis, Elizabeth A. , Fox, David A. , Mikuls, Ted R. , Walker, Sarah, Keyes-Elstein, Lynette

Mayo Clinic

Arthritis & Rheumatology | August 30, 2025 | Volume: 78 | Issue: 4 | Pages: 809-820

10.1002/art.43366 | PMID 40884017 Get It

Objective Individuals with serum elevations of anti–cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such at‐risk individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence. Methods In this phase 2 randomized trial, individuals at risk for RA with anti‐CCP3 ≥2 times the upper limit of normal (ULN) were assigned to receive HCQ or placebo for 12 months, with up to 24 months of postdrug follow‐up. The primary outcome was the development of clinical RA, as defined in the protocol, at 36 months. Secondary outcomes included safety, development of inflammatory arthritis (IA), and participant‐reported joint symptoms. Results Of 144 randomized participants, 71 were assigned to HCQ and 73 to placebo. In the modified intent‐to‐treat population, clinical RA occurred in 21 of 69 (30.4%) participants in the HCQ group and 24 of 73 (32.9%) in the placebo group. The risk of clinical RA at 36 months was 0.336 with HCQ and 0.394 with placebo (difference −0.058; 95% confidence interval −0.336 to 0.220; P = 0.52). Results for IA were similar. The occurrence and severity of joint symptoms were not observed to differ between groups. Adverse event incidence was similar between groups. Conclusion In this trial involving individuals with anti‐CCP3 levels ≥2 times the ULN, 12 months of HCQ did not prevent the development of clinical RA at 36 months. image
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia
Fortuna, Gliceida Galarza , Peres, Lauren C. , Corraes, Andre De Menezes Silva , Hovanky, Vanna, Shune, Leyla , McGuirk, Joseph P. , Avilla, Gabriel De, Khouri, Jack , Dima, Danai , Gaballa, Mahmoud , Dhakal, Binod , Forsberg, Peter A. , Godara, Amandeep , Afrough, Aimaz , Anderson, Larry D. , Davis, James A. , Mann, Hashim , Purvey, Sneha , Clark, William , Htut, Myo, Ferreri, Christopher J. , Voorhees, Peter M. , Hashmi, Hamza , Patel, Krina K. , Sidana, Surbhi , Lin, Yi, Sborov, Douglas W. , Galarza Fortuna, Gliceida M , De Menezes Silva Corraes, Andre , McGuirk, Joseph , Khouri, Jack , Dima, Danai , Dhakal, Binod , Godara, Amandeep , Anderson, Larry D , Herr, Megan M. , Davis, James A , Mann, Hashim , Kocoglu, Mehmet H , Voorhees, Peter , Patel, Krina , Sidana, Surbhi , Hansen, Doris K , Sborov, Douglas W , Назаренко, Елена Борисовна , Avilla, Gabriel De, Clark, William, Htut, Myo , Beitinjaneh, Amer , Pereira, Denise L. , Kocoglu, Mehmet H. , Atrash, Shebli , Rossi, Adriana , Richard, Shambavi , Hansen, Doris K.

Mayo Clinic

Blood Advances | August 28, 2025 | Volume: 9 | Issue: 23 | Pages: 6009-6018

10.1182/bloodadvances.2025016966 | PMID 40875887 Get It

Abstract Despite significant therapeutic advances in multiple myeloma (MM), outcomes in patients with plasma cell leukemia (PCL) remain dismal. We conducted a multicenter retrospective analysis of patients with PCL who were treated with the B-cell maturation antigen–directed chimeric antigen receptor T-cell (CAR-T) products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). We identified 34 patients; 19 patients received ide-cel and 15 received cilta-cel. With a median follow-up of 11.9 months, the overall median progression-free survival (mPFS) was 9.0 months (95% confidence interval [CI], 4-15) and the median overall survival (mOS) was 13.0 months (95% CI, 8 to not estimable [NE]). The 1-year cumulative incidence of progression or death was 72%, and the 1-year cumulative incidence of death was 47%. Patients who received cilta-cel had a longer mPFS (19.0 months vs 6.0 months) and mOS (&gt;23 months [NE] vs 9.0 months) when compared with those treated with ide-cel. Similarly, the 1-year cumulative incidence of disease progression or death was 37.5% (95% CI, 17.4-68.5) with cilta-cel, whereas all patients treated with ide-cel progressed or died within 12 months of infusion. The rates of hematologic and nonhematologic toxicities were similar between patients treated with cilta-cel and those treated with ide-cel and were consistent with those reported in patients with MM. In this first multicenter study that evaluated patients with PCL who were treated with standard-of-care CAR-T products, we show that CAR-T is safe, feasible, and associated with improved outcomes when compared with historic standards.
A Mixed-Method Case Study to Evaluate Adoption of Clinical Decision Support for Cancer Symptom Management
Ridgeway, Jennifer L. , Pachman, Deirdre R. , Chlan, Linda L, Tofthagen, Cindy , Tobin, Kyle A., Grzegorcyzk, Veronica, Rahman, Parvez, Ruddy, Kathryn J. , Minteer, Sarah A. , Tofthagen, Cindy S , Ridgeway, Jennifer L , Rutten, Lila J. Finney , Griffin, Joan M. , Austin, Jessica D. , Chlan, Linda L. , Tobin, Kyle A., Cheville, Andrea

Mayo Clinic

Applied Clinical Informatics | August 22, 2025 | Volume: 16 | Issue: 04 | Pages: 804-814

10.1055/a-2587-6081 | PMID 40846308 Get It

AbstractElectronic patient-reported outcome measures (ePROMs) can improve care for people with cancer, but effectiveness hinges on well-supported integration in clinical settings.We evaluated clinician use of specific clinical decision support (CDS) tools in the electronic health record (EHR) designed to facilitate timely, clinically appropriate responses to ePROM scores for six symptoms commonly experienced by cancer patients.The parent pragmatic trial, which took place at Mayo Clinic (Rochester, Minnesota, United States) and its affiliated community health care system between March 2019 and January 2023, evaluated the population-level effectiveness and implementation of an ePROM surveillance and EHR-facilitated collaborative care symptom management intervention. The present evaluation used a case study approach with four data sources: (1) clinician interactions with CDS tools abstracted from the EHR; (2) clinician notes identified with an institution-specific textual search tool; (3) qualitative interviews and group discussions with care teams; and (4) administrative records reviewed to identify training and outreach to care teams.EHR metrics showed very low adoption of CDS tools including alerts and symptom-specific order sets, despite educational outreach and information technology support provided to clinical care teams. Qualitative findings revealed that CDS use was not easy to integrate into busy clinical workflows and highlighted clinician perceptions that the collaborative care intervention provided additional patient support that reduced clinicians' need to utilize CDS tools. They also highlight the importance of contextual factors, including institutional priorities and EHR changes.This pragmatic clinical trial case study found limited adoption of EHR CDS tools that had been developed to increase clinicians' awareness of and responses to ePROM data. Findings suggest the need to align clinician and organizational implementation strategies, simplify CDS tools to fit practice expectations, and identify and address contextual factors that could undercut strategies like education and peer support. This may be especially important for teams who aim to iteratively evaluate and refine CDS and implementation strategies for multicomponent interventions or introduce new strategies that are responsive to barriers while maintaining scalability.